Effects of Clenbuterol on Body Composition and Strength Following Resistance Training, Detraining, and Retraining in Healthy Adults: A Randomized Controlled Trial

BACKGROUND: -adrenoceptor agonist, is commonly used off-label in conjunction with resistance training to increase muscle mass and decrease fat mass. However, the long-term effects on body composition and strength with use and following discontinuation of use remain unexplored. OBJECTIVE: The aim of the study was to investigate the effects of clenbuterol on body composition and strength during a resistance training intervention, as well as the long-term effects of prior use of clenbuterol during detraining and subsequent retraining in healthy young men and women. METHODS: This randomized, double-blinded, placebo-controlled trial was conducted at the University of Copenhagen, Denmark, between March 2023 and March 2025. Thirty-two healthy men (26 ± 3 years; mean ± SD; n = 16) and women (25 ± 5 years; n = 16) completed 8 weeks of resistance training with daily ingestion of clenbuterol (80 μg) (n = 16) or placebo (n = 16). This was followed by 16 weeks of detraining and another 8 weeks of resistance training. Before the intervention and after each training and detraining period, body composition was assessed by dual-energy X-ray absorptiometry (DXA) and strength was assessed by leg press and bench press 1-repetition maximum (1RM). RESULTS: Clenbuterol increased gains in lean mass (+ 1.7 kg, p < 0.001) and 1RM bench press (+ 6 kg, p < 0.001) and leg press (+ 16 kg, p = 0.001) during 8 weeks of resistance training compared with placebo, with a more pronounced effect in males than females (lean mass: p = 0.003; 1RM bench press: p < 0.001), whereas the decrease in fat mass did not differ between clenbuterol and placebo (p = 0.614). Following cessation of clenbuterol, detraining decreased lean mass (p < 0.001), 1RM bench press (p < 0.001), and 1RM leg press (p = 0.026) to a greater extent in the clenbuterol group, such that initial changes in lean mass (p = 0.363) and 1RM bench press (p = 0.834) no longer differed from placebo, whereas 1RM leg press remained elevated in the clenbuterol group (p = 0.041). Retraining increased lean mass and 1RM leg press with no differences between the clenbuterol and placebo group (lean mass: p = 0.393; 1RM leg press: p = 0.662), whereas the increase in 1RM bench press was greater in the clenbuterol group (+ 3 kg, p = 0.047). CONCLUSION: Clenbuterol markedly augments training-induced gains in lean mass and strength. After discontinuation, prior clenbuterol exposure does not enhance retraining-induced lean mass gains, but some strength-related advantages persist. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT05692856.

Authors

Institutions

Publication Details

Journal
Sports Medicine
Published
2026-09-12
DOI
https://doi.org/10.1007/s40279-026-02522-4
Primary Topic
Pharmacological Effects and Assays
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Effects of Clenbuterol on Body Composition and Strength Following Resistance Training, Detraining, and Retraining in Healthy Adults: A Randomized Controlled Trial

Søren Jessen, Yvette Dehnes, Lukas Moesgaard, Morten Hostrup et al.
Sports Medicine
Pharmacological Effects and Assays
article

Effects of Clenbuterol on Body Composition and Strength Following Resistance Training, Detraining, and Retraining in Healthy Adults: A Randomized Controlled Trial

Søren Jessen, Yvette Dehnes, Lukas Moesgaard, Morten Hostrup, Jens Bangsbo, Vibeke Backer, Sebastian Skov Uhrenholt, Rasmus Blak Hasgaard
article en

Abstract

BACKGROUND: -adrenoceptor agonist, is commonly used off-label in conjunction with resistance training to increase muscle mass and decrease fat mass. However, the long-term effects on body composition and strength with use and following discontinuation of use remain unexplored. OBJECTIVE: The aim of the study was to investigate the effects of clenbuterol on body composition and strength during a resistance training intervention, as well as the long-term effects of prior use of clenbuterol during detraining and subsequent retraining in healthy young men and women. METHODS: This randomized, double-blinded, placebo-controlled trial was conducted at the University of Copenhagen, Denmark, between March 2023 and March 2025. Thirty-two healthy men (26 ± 3 years; mean ± SD; n = 16) and women (25 ± 5 years; n = 16) completed 8 weeks of resistance training with daily ingestion of clenbuterol (80 μg) (n = 16) or placebo (n = 16). This was followed by 16 weeks of detraining and another 8 weeks of resistance training. Before the intervention and after each training and detraining period, body composition was assessed by dual-energy X-ray absorptiometry (DXA) and strength was assessed by leg press and bench press 1-repetition maximum (1RM). RESULTS: Clenbuterol increased gains in lean mass (+ 1.7 kg, p < 0.001) and 1RM bench press (+ 6 kg, p < 0.001) and leg press (+ 16 kg, p = 0.001) during 8 weeks of resistance training compared with placebo, with a more pronounced effect in males than females (lean mass: p = 0.003; 1RM bench press: p < 0.001), whereas the decrease in fat mass did not differ between clenbuterol and placebo (p = 0.614). Following cessation of clenbuterol, detraining decreased lean mass (p < 0.001), 1RM bench press (p < 0.001), and 1RM leg press (p = 0.026) to a greater extent in the clenbuterol group, such that initial changes in lean mass (p = 0.363) and 1RM bench press (p = 0.834) no longer differed from placebo, whereas 1RM leg press remained elevated in the clenbuterol group (p = 0.041). Retraining increased lean mass and 1RM leg press with no differences between the clenbuterol and placebo group (lean mass: p = 0.393; 1RM leg press: p = 0.662), whereas the increase in 1RM bench press was greater in the clenbuterol group (+ 3 kg, p = 0.047). CONCLUSION: Clenbuterol markedly augments training-induced gains in lean mass and strength. After discontinuation, prior clenbuterol exposure does not enhance retraining-induced lean mass gains, but some strength-related advantages persist. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT05692856.

Sports Medicine
University of Copenhagen (DK), Oslo University Hospital (NO), Bispebjerg Hospital (DK), Copenhagen University Hospital (DK), Karolinska Institutet (SE), Swedish School of Sport and Health Sciences (SE), IT University of Copenhagen (DK)
Københavns Universitet, World Anti-Doping Agency
Good health and well-being
Openalex Percentile: Top 14%
Pharmacological Effects and Assays
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.